REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 149 filers reported holding REATA PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.53 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $1,491,000 | +224.1% | 45,505 | +160.6% | 0.00% | – |
Q4 2021 | $460,000 | -91.2% | 17,462 | -66.5% | 0.00% | -100.0% |
Q3 2021 | $5,251,000 | -39.7% | 52,188 | -15.1% | 0.00% | -40.0% |
Q2 2021 | $8,702,000 | +64.3% | 61,482 | +15.7% | 0.01% | +66.7% |
Q1 2021 | $5,298,000 | -15.0% | 53,136 | +5.4% | 0.00% | -25.0% |
Q4 2020 | $6,231,000 | +213.6% | 50,403 | +147.1% | 0.00% | +300.0% |
Q3 2020 | $1,987,000 | -46.4% | 20,397 | -14.1% | 0.00% | -66.7% |
Q2 2020 | $3,706,000 | +16.2% | 23,751 | +7.5% | 0.00% | 0.0% |
Q1 2020 | $3,190,000 | -43.6% | 22,101 | -20.1% | 0.00% | -25.0% |
Q4 2019 | $5,656,000 | +285.5% | 27,665 | +51.4% | 0.00% | +300.0% |
Q3 2019 | $1,467,000 | -51.0% | 18,275 | -42.4% | 0.00% | -50.0% |
Q2 2019 | $2,991,000 | +15.2% | 31,703 | +4.3% | 0.00% | 0.0% |
Q1 2019 | $2,597,000 | +122.9% | 30,385 | +46.3% | 0.00% | +100.0% |
Q4 2018 | $1,165,000 | -28.1% | 20,769 | +4.8% | 0.00% | 0.0% |
Q3 2018 | $1,620,000 | – | 19,814 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Conrad N. Hilton Foundation | 63,481 | $7,847,000 | 100.00% |
CPMG Inc | 2,896,901 | $358,115,000 | 55.16% |
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 140,000 | $17,307,000 | 26.62% |
Corriente Advisors, LLC | 525,000 | $64,901,000 | 15.45% |
DUMAC, INC. | 76,050 | $9,401,000 | 7.33% |
MADDEN SECURITIES Corp | 35,152 | $4,345,000 | 2.80% |
Biondo Investment Advisors, LLC | 113,692 | $14,055,000 | 2.69% |
Duquesne Family Office | 749,897 | $92,702,000 | 2.50% |
LBJ Family Wealth Advisors, Ltd. | 30,368 | $3,754,000 | 2.44% |
Integral Health Asset Management, LLC | 50,000 | $6,181,000 | 1.84% |